Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex

ID
Name
TOF-Sugammadex
Description
This study is a prospective observational study. A total 52 patients will be included in this study. We will observe the incidence of postoperative residual neuromuscular blockade in patients receiving sugammadex.
Trial arms
Trial start
2023-03-15
Estimated PCD
2023-08-31
Trial end
2024-08-31
Status
Recruiting
Treatment
Sugammadex
At the end of surgery, neuromucular blockade will be reversed with 2mg/kg or 4mg/kg sugammadex depending on the depth of neuromuscular blockade.
Size
52
Primary endpoint
Postoperative residual neuromuscular blockade
On the arrival of PACU
Eligibility criteria
Inclusion Criteria: * Patients undergoing elective surgery under general anesthesia. * American Society of Anesthesiologists grade 1, 2, or 3. * Aged \>18 years Exclusion Criteria: * Refusal to participate in the study * Body Mass Index \< 18.5 kg/m2 or \> 35 kg/m2 * History of neuromuscular disease. * History of allergy to neuromuscular blockade * Scheduled to transfer to the intensive care unit
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 52, 'type': 'ESTIMATED'}}
Updated at
2023-04-14

1 organization

1 product

1 indication

Organization
Seoul National University Hospital
Product
Sugammadex
Indication
Postoperative Residual Curarization